Advertisement

Tumoren des lymphatischen Systems

  • H.T. Eich
  • J. Kriz
  • M. Bischof
Chapter

Zusammenfassung

Der M. Hodgkin ist eine seltene Erkrankung, die Häufigkeit beträgt etwa 0,7 % aller bösartigen Erkrankungen und die Todesrate liegt bei etwa 0,3 % aller Todesfälle durch Malignome. Die Morbidität liegt bei etwa 3,1 pro 100.000 Einwohner, Männer sind etwas häufiger betroffen als Frauen (1,1:1), die Altersverteilung weist 2 Gipfel auf, zwischen 25 und 35 Jahren und zwischen 60 und 75 Jahren.

Literatur

Zu Morbus Hodgkin

  1. Aleman BM, Raemaekers JM, Tirelli U et al. (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348 (24) 2396–2406PubMedGoogle Scholar
  2. Aleman BM, Raemaekers JM, Tomiŝiĉ R et al. (2007) Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 67 (1) 19–30PubMedGoogle Scholar
  3. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109 (5): 1878–1886PubMedGoogle Scholar
  4. Anderson H, Crowther D, Deakin DP, Ryder WDJ, Radford JA (1991) A randomized study of adjuvant MVPP chemotherapy after mentle radiotherapy in pathological staged IA-IIB Hodgkin’s disease: 10-year follow-up. Ann Oncol 2:49PubMedGoogle Scholar
  5. Andrieu J, Coscas Y, Kramer P et al. (1985) Chemotherapy plus radiotherapy in clinical stage IA-IIIB Hodgkin’s disease. Results of the H77 trial (1977–1980). In: Cavalli F, Bonadonna G, Rosencweig M (eds) Malignant lymphomas and Hodgkin’s disease: experimental and therapeutic advances. Martinus Nijhoff, Dordrecht, pp 353–361Google Scholar
  6. Angel CA, Warford A, Campbell AC, Pringle JH, Lauder I (1987) The immunohistology of Hodgkin’s disease – Reed-Sternberg cells and their variants. J Pathol 153:21–30PubMedGoogle Scholar
  7. Ballova V, Rüffer JU, Haverkamp H et al. (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16 (1):124–131PubMedGoogle Scholar
  8. Bar-Shalom R, Israel O, Harim N et al. (1996) Diffuse lung uptake of Ga-67 after treatment of lymphoma: Is it of clinical importance? Radiology 199:473–476PubMedGoogle Scholar
  9. Bartlett N, Rosenberg S, Hoppe R, Hancock S, Horning S (1995) Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 13:1080–1088PubMedGoogle Scholar
  10. Barton M, Boyages J, Crennan E et al. (1995) Radiation therapy for early stage Hodgkin’s disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group. Int J Radiat Oncol Biol Phys 31:227–236PubMedGoogle Scholar
  11. Bates N, Williams M, Bessell E, Hudson G, Hudson B (1994) Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved field radiotherapy and clinical stage IA and IIA Hodgkin’s disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 12:288–296PubMedGoogle Scholar
  12. Bathia S, Robinson LL, Oberlin O et al. (1996) Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 334:745–751Google Scholar
  13. Bennett MH, MacLennan KA, Hudson BV, Hudson GV (1990) The clinical and prognostic relevance of histopathologic classification in Hodgkin’s disease. Prog Surg Pathol 10:127Google Scholar
  14. Bierman P, Bagin R, Jagannath S et al. (1993) High dose chemotherapy followed by autologous hematopoetic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 4:767PubMedGoogle Scholar
  15. Biti G, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10:378–382PubMedGoogle Scholar
  16. Biti G, Celai E, Magrini SM, Papi MG, Ponticelli P, Boddi V (1994) Second solid tumors and leukemia after treatment for Hodgkin’s disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 29:25–31PubMedGoogle Scholar
  17. Bjorkholm M, Holm M, Mellstedt H (1977) Immunologic profile in patients with cured Hodgkin’s disease. Scand J Haematol 19:361–368Google Scholar
  18. Bloomfield C, Pajak T, Glicksman A et al. (1982) Chemotherapy and combined modality therapy for Hodgkin’s disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep 66:835–846PubMedGoogle Scholar
  19. Bonadonna G (1982) Chemotherapy strategies to improve the control of Hodgkin’s disease. The Richard and Hina Rosenthal Foundation Award Lecture. Cancer Res 42:4309–4320PubMedGoogle Scholar
  20. Bonadonna G, Zucali R, Monfardini S, Lena MD, Uslenghi C (1975) Combination chemotherapy of Hodgkin’s disease with adriamycine, bleomycine, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259PubMedGoogle Scholar
  21. Borchmann P, Haverkamp H, Diehl V et al. (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group Nov 10;29(32):4234–4242Google Scholar
  22. Brizel DM, Gockerman JP, Crawford J et al. (1994) A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin’s disease. Cancer 74:159–163PubMedGoogle Scholar
  23. Brown A, Urie M, Barest G et al. (1991) Three-dimensional photon treatment planning for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 21:205–215PubMedGoogle Scholar
  24. Canellos G, Young RC, DeVita VD (1972) Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharm Ther 13:750Google Scholar
  25. Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478PubMedGoogle Scholar
  26. Canellos GP, Horvich A (1999) Management of recurrent Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 507–519Google Scholar
  27. Carbone PP, Kaplan H, Musshoff K (1971) Report of the committee on Hodgkin’s disease staging. Cancer Res 31:1860–1861PubMedGoogle Scholar
  28. Carde P, Burgers JM, Henry-Amar M et al. (1988) Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239–252PubMedGoogle Scholar
  29. Carde P, Hagenbeek A, Hayat M et al. (1993) Clinical staging versus laparotomy and combine modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258–2272PubMedGoogle Scholar
  30. Carde P, Noordijk E, Hagenbeek A et al. (1997) Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 16:13 (abst)Google Scholar
  31. Carmel RJ, Kaplan HS (1976) Mantle irradiation in Hodgkin’s disease – an analysis of technique, tumor eradication, and complications. Cancer 37:2813–2825PubMedGoogle Scholar
  32. Castellino R, Dunnick N, Goffinet D et al. (1983) Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 1:532PubMedGoogle Scholar
  33. Coia L, Hanks G (1988) Complications from large field intermediate dose infradiaphragmatic radiation: An analysis of the patterns of care outcome studies for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 15:29–35PubMedGoogle Scholar
  34. Coltman C, Myers J, Montague E et al. (1982) The role of combined radiotherapy and chemotherapy in the primary management of Hodgkin’s disease. In: Rosenberg S, Kaplan H (eds) Malignant lymphomas: etiology, immunology, pathology, treatment. Academic Press, pp 523–536Google Scholar
  35. Connors JM, Yahalom J, Noordijk EM (1999) Principles of combined-modality therapy in Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 395–407Google Scholar
  36. Cosset J, Ferme C, Noordijk E (1996) Combined modality therapy for poor prognosis stages I and II Hodgkin’s disease. Semin Radiat Oncol 6:185PubMedGoogle Scholar
  37. Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM (1987) Stage I to IIB Hodgkin’s disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 5:1041–1049PubMedGoogle Scholar
  38. Davis AB (1911) Report of a case of Hodgkin’s disease complicated by pregnancy. Bull Lying-in Hosp NY 7:151–158Google Scholar
  39. De Bruin ML, Sparidans J, van’t Veer MB, et al. (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246PubMedGoogle Scholar
  40. DeVita VT, Simon RM, Hubbard SM et al. (1980) Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients in the National Cancer Institute. Ann Intern Med 92:587–595PubMedGoogle Scholar
  41. Diehl V, Pfreundschuh M, Loeffler M et al. (1987) Therapiestudien der Deutschen Hodgkin Studiengruppe. Zwischenergebnisse der Studienprotokolle HD1, HD2 und HD3. Onkologie 10:62–66PubMedGoogle Scholar
  42. Diehl V, Loeffler M, Pfreundschuh M et al. (1995) Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin’s disease. German Hodgkin Study Group (GHSG). Ann Oncol 6:901–910PubMedGoogle Scholar
  43. Diehl V, Sieber M, Rüffer U et al. (1997) BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s Lymphoma Group. Ann Oncol 8:143–148PubMedGoogle Scholar
  44. Diehl V, Franklin J et al. (1998 a) BEACOPP: A new regimen for advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 9 (Suppl 5):67–71Google Scholar
  45. Diehl V, Franklin J, Hasenclever D et al. (1998 b) BEACOPP, a new dose-escalated and accelerated regimen, at least as effective as COPP/ABVD in patients with advanced stage Hodgkin lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 16:3810–3821PubMedGoogle Scholar
  46. Diehl V, Sextro M, Franklin J et al. (1999) Clinical presentation, course, and prognosis factors in lymphocyte-predominant Hodgkin’s disease: a report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s disease. J Clin Oncol 17:776PubMedGoogle Scholar
  47. Diehl V, Franklin J, Pfreundschuh M, et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 348 (24) 2386–2395PubMedGoogle Scholar
  48. Dühmke E, Diehl V, Loeffler M et al. (1996) Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended-field radiotherapy alone. Int J Radiat Oncol Biol Phys 36:305–310PubMedGoogle Scholar
  49. Dühmke E, Franklin J, Pfreundschuh M et al. (2001) Low dose radiation is sufficient for noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914PubMedGoogle Scholar
  50. Dunn J (1994) Doxorubicin-induced cardiomyopathy. J Pediatr Oncol Nurs 11:152–160PubMedGoogle Scholar
  51. Dutcher J, Wiernik P (1985) Combined modality treatment of Hodgkin’s disease confined to lymph nodes. Dev Oncol 32:317–327Google Scholar
  52. Easson E, Russel M (1963) The cure of Hodgkin’s disease. Br J Med 1:1704–1707Google Scholar
  53. Eich HT, Diehl V, Goergen H, et al. Intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavorable Hodgkin lymphoma: Final analysis of the German Hodgkin Study Group (GHSG) HD11 trial. J Clin Oncol 2010: in pressGoogle Scholar
  54. Eich HT, Engenhart-Cabillic R, Hansemann K, et al. (2008) Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin´s lymphoma – an analysis of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 2008; 71(5):1419–1424.PubMedGoogle Scholar
  55. Eich HT, Gossmann A, Engert A, et al. (2007) A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin’s lymphoma - analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 69 (4):1187–1192.PubMedGoogle Scholar
  56. Eich HT, Haverkamp U, Engert A et al. (2005) Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin’s Lymphoma – a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 63 (3):860–865PubMedGoogle Scholar
  57. Eich HT, Müller R-P (2005) The radiotherapy reference panel - experiences and results of the German Hodgkin Study Group (GHSG). Eur J Haematol 75 (Suppl 66) 98–105Google Scholar
  58. Eich HT, Müller R-P (2007) Current role and future developments of radiotherapy in early-stage favourable Hodgkin’s lymphoma. Strahlenther Onkol (Sondernr 2) 16–18Google Scholar
  59. Eich HT, Müller R-P, Engenhart-Cabillic R, et al. (2008) Involved Node Radiotherapy in early-stage Hodgkin’s Lymphoma – Definition and Guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol; 184 (8):406–410PubMedGoogle Scholar
  60. Eich HT, Müller RP, Schneeweiss A et al. (2004 a) Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 58:805–808PubMedGoogle Scholar
  61. Eich HT, Staar S, Gossmann A et al. (2004b) Centralized radiation oncological review of cross-sectional imaging of Hodgkin’s disease leads to significant changes of the required involved field – results of a quality assurance program of the German Hodgkin Study Group (GHSG). Int J Radiat Oncol Biol Phys 58:1121–1127Google Scholar
  62. Eich HT, Zimmermann C, Müller R-P. 2010)Involved-Node-Radiotherapie in frühen Stadien des Hodgkin-Lymphoms. Onkologe 2010;16:35–40Google Scholar
  63. Ekstrand BC, Lucas JB, Horwitz SM et al. (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101 (11):4285–4289PubMedGoogle Scholar
  64. Engert A, Schiller P, Josting A, et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma Study Group. J Clin Oncol 21 (19):3601–3608PubMedGoogle Scholar
  65. Engert A, Ballova V, Haverkamp H et al. (2005) Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s Study Group. J Clin Oncol 23 (22):5052–5060PubMedGoogle Scholar
  66. Engert A, Franklin J, Eich HT et al. (2007) Two cycles of ABVD plus extended field radiotherapy is superior to radiotherapy alone in early-favourable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25 (23):3495–3502PubMedGoogle Scholar
  67. Engert A, Diehl V, Franklin J al. (2009) BEACOPPescalated in the treatment of patients with advanced-stage Hodgkin Lymphoma: 10 years follow-up of the GHSG HD9 study. J Clin Oncol. Sep 20;27(27):4548–4554PubMedGoogle Scholar
  68. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P et al. (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652PubMedGoogle Scholar
  69. Engert A, Haverkamp H, Kobe C et al. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet May 12;379(9828):1791–1799Google Scholar
  70. Erdkamp FL, Breed WP, Bosch LJ, Wijnen JT, Blijham GB (1992) Hodgkin’s disease in the elderly. Cancer 70:830PubMedGoogle Scholar
  71. Fabian CJ, Mansfield CM, Dahlberg S et al. (1994) Low-dose involved-field radiation after chemotherapy in advanced Hodgkin’s disease. Ann Intern Med 120:903–912PubMedGoogle Scholar
  72. Fermé C, Eghbali H, Meerwaldt JH, et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med.357(19):1916–1927PubMedGoogle Scholar
  73. Fletcher GH, Shukovsky LJ (1975) The interplay of radiocurability and tolerance in the irradiation of human cancers. J Radiol Electrol Med Nucl 56:383–400PubMedGoogle Scholar
  74. Gallamini A, Hutchings M, Rigacci L et al. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (24):3746–3752PubMedGoogle Scholar
  75. Gehan E, Sullivan M, Fuller L et al. (1990) The intergroup Hodgkin’s disease study in children. Cancer 65:1429–1437PubMedGoogle Scholar
  76. Gelb AB, VandeRijn M, Warnke RA (1996) Pregnancy-associated lymphomas. A clinico-patologic study. Cancer 78:304PubMedGoogle Scholar
  77. Gilbert R (1925) La roentgentherapie de la granulomatose maligne. J Radiol Electrol 9:509–514Google Scholar
  78. Gilbert R (1939) Radiotherapy in Hodgkin’s disease (malignant granulomatosis); anatomic and clinical foundations; governing principles, results. Am J Roentgenol 41:198–241Google Scholar
  79. Gilbert R, Babaiantz L (1931) Notre methode de roentgentherapie de la lymphogranulomatose (Hodgkin); resultats eloignes. Acta Radiol 12:523–529Google Scholar
  80. Ginzton E, Mallory K, Kaplan H (1957) The Stanford medical linear accelerator I: design and development. Stanford Med Bull 15:123–140PubMedGoogle Scholar
  81. Girinsky T, van der Maazen R, Specht L et al. (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79 (3) 270–277PubMedGoogle Scholar
  82. Glaser S, Lin R, Stewart S et al. (1997) Eppstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer 70:375PubMedGoogle Scholar
  83. Glatstein E, Guernsey J, Rosenberg S, Kaplan H (1969) The value of laparotomy and splenectomy in staging of Hodgkin’s disease. Cancer 24:709–718PubMedGoogle Scholar
  84. Goldie JH, Coldmann AJ (1979) A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatm Rep 63:1727–1733Google Scholar
  85. Gomez G, Sullivan M, Fuller L et al. (1984) Large mediastinal mass in Hodgkin’s disease. Results of two treatment modalities. Am J Clin Oncol 6:65–73Google Scholar
  86. Gross NJ (1977) Pulmonary effects of radiation therapy. Ann Intern Med 86:81–92PubMedGoogle Scholar
  87. Hagemeister F, Fuller L, Velasquez W et al. (1982) Stage I and II Hodgkin’s disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 66: 789–798PubMedGoogle Scholar
  88. Hancock S, Hoppe R, Horning S (1988) Intercurrent death after Hodgkin’s disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 109:183PubMedGoogle Scholar
  89. Hancock S, Cox R, Dougall IM (1991) Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 325:599–605PubMedGoogle Scholar
  90. Hancock S, Tucker MA, Hoppe RT (1993 a) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31PubMedGoogle Scholar
  91. Hancock SL, Tucker MA, Hoppe RT (1993 b) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270:1949–1955PubMedGoogle Scholar
  92. Hancock SL, Donaldson SS, Hoppe RT (1993 c) Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 7:1208–1215Google Scholar
  93. Hancock S, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6:225–242PubMedGoogle Scholar
  94. Hanks G, Kinzie J, White R, Herring D, Kramer S (1983) Patterns of care outcome studies: Results of national practice in Hodgkin’s disease. Cancer 51:569–573PubMedGoogle Scholar
  95. Hansmann ML, Wacker HH, Radzun HJ (1986) Paragranuloma is a variant of Hodgkin’s disease with predominance of B-cells. Virchows Arch A 409:171–181Google Scholar
  96. Harris NL, Jaffe ES, Stein H (1994) European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361PubMedGoogle Scholar
  97. Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. Ann Oncol 7 (Suppl 4):95–98PubMedGoogle Scholar
  98. Haybittle J, Easterling M, Bennett M et al. (1985) Review of British National Lymphoma Investigation Studies of Hodgkin’s disease and development of prognostic index. Lancet 1:967–972PubMedGoogle Scholar
  99. Henry-Amar M (1992) Second cancer after the treatment of Hodgkin’s disease – a report from the international Database on Hodgkin’s disease. Ann Oncol 3 (Suppl 4):117–128PubMedGoogle Scholar
  100. Henry-Amar M, Friedman S, Hayat M et al. (1991) Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin’s disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 114:361–365PubMedGoogle Scholar
  101. Herbst C, Rehan FA, Brillant C et al. (2001) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 95 (3):494–500Google Scholar
  102. Hirsch A, Els NV, Straus DJ et al. (1996) Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol 14:1297–1305PubMedGoogle Scholar
  103. Hodgkin T (1832) On some morbid experiences of the absorbent glands and spleen. Med Chir Trans 17:69–97Google Scholar
  104. Hoogstraten B, Holland J, Kramer S et al. (1973) Combination chemotherapy radiotherapy for stage III Hodgkin’s disease. Arch Intern Med 131:424–428PubMedGoogle Scholar
  105. Hoppe RT (1983) The definitive management of limited and intermediate stages of Hodgkin’s disease with radiotherapy alone. In: Bennett JM (ed) Controversies in the management of lymphomas. Nijhoff, Dordrecht, pp 129–150Google Scholar
  106. Hoppe RT (1996) Hodgkin’s disease – the role of radiation therapy in advanced disease. Ann Oncol 7 (Suppl 4):99–103PubMedGoogle Scholar
  107. Hoppe RT, Coleman CN, Cox RS, Rosenberg SA, Kaplan HS (1982) The management of stage I-II Hodgkin’s disease with irradiation allone or combined modality therapy: the Stanford experience. Blood 59:455–465PubMedGoogle Scholar
  108. Hoppe R, Horning S, Hancock S, Rosenberg S (1989) Current Standford clinical trials for Hodgkin’s disease. Recent results in cancer research. Springer, Berlin Heidelberg New York TokioGoogle Scholar
  109. Hoppe RT, Cosset JM, Santoro A, Wolf J (1999) Treatment of unfavorable prognosis stage I-II Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 459–481Google Scholar
  110. Horning SJ, Hoppe RT, Rosenberg SA (1984) The Stanford Hodgkin’s disease trials 1967–1983. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer IV. Grune & Stratton, New YorkGoogle Scholar
  111. Horning S, Hoppe R, Hancock S (1988) Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 6:1822PubMedGoogle Scholar
  112. Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA (1994) Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 12:297–305PubMedGoogle Scholar
  113. Horning SJ, Bennett JM, Bartlett NL, Williams J, Neuberg D, Casileth P (1996) 12 weeks of chemotherapy stanford V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin’s disease: a limited institution ECOG pilot study. Blood 88:2681 (abst)Google Scholar
  114. Horning SJ, Hoppe RT, Mason J et al. (1997) Stanford-Kiaiser Permanente G1 study for clinical stage I to IIA Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736–1744PubMedGoogle Scholar
  115. Hudson MM, Greenwald C, Thompson E (1993) Efficacy and toxicity of multiagent chemotherapy and low-dose involvedfield radiotherapy in children and adolescents with Hodgkin’s disease. J Clin Oncol 11:100–108PubMedGoogle Scholar
  116. Hunger SP, Link MP, Donaldson SS (1994) ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience. J Clin Oncol 12:2160–2166PubMedGoogle Scholar
  117. Hutchinson GB (1976) Survival and complications of radiotherapy following involved and extended field radiotherapy of Hodgkin’s disease stage I and II. A collaborative study. Cancer 38:288–305.Google Scholar
  118. Hutchinson G, Allison R, Fuller L et al. (1984) Collaborative study: radiotherapy of stage I and II Hodgkin’s disease. Cancer 54:1928–1942 alone.Google Scholar
  119. Hutchings M, Loft A, Hansen M, et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 107 (1):52–59PubMedGoogle Scholar
  120. Hutchings M, Loft A, Hansen M et al. (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 78 (3):206–212PubMedGoogle Scholar
  121. Jackson H, Parker F (1944) Hodgkin’s disease. II Pathology. N Engl J Med 231:35–44Google Scholar
  122. Johnson R, Thomsa L, Schneiderman M et al. (1970) Preliminary experience with total nodal irradiation in Hodgkin’s disease. Radiology 96:603–608PubMedGoogle Scholar
  123. Josting A, Katay I, Rueffer U et al. (1998) Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289PubMedGoogle Scholar
  124. Josting A, Rueffer U, Franklin J et al. (1999) Prognostic factors and treatment outcome in patients with primary progressive Hodgkin’s lymphoma – a report from the German Hodgkin’s Disease Study Group (GHSG). Blood 10 (Suppl 1):2299aGoogle Scholar
  125. Josting A, Reiser M, Rueffer U (2000) Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s disease – Is there a chance for cure? J Clin Oncol 18:332PubMedGoogle Scholar
  126. Josting A, Nogova L, Franklin J et al. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s Lymphoma: A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 23 (7):1522–1529PubMedGoogle Scholar
  127. Juweid ME (2006) Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 510-1:259–265Google Scholar
  128. Kaldor J, Day N, Bell J et al. (1992) Lung cancer following Hodgkin’s disease: a case-control study. Int J Cancer 52:677PubMedGoogle Scholar
  129. Kaplan H (1962) The radical radiotherapy of Hodgkin’s disease. Radiology 78:553–561PubMedGoogle Scholar
  130. Kaplan H (1966 a) Long-term results of palliative and radical radiotherapy of Hodgkin’s disease. Cancer Res 26:1250–1252PubMedGoogle Scholar
  131. Kaplan HS (1980) Hodgkin’s disease, 2nd edn. Harvard University Press, CambridgeGoogle Scholar
  132. Kaplan HS, Rosenberg SA (1966) Extended-field radical radiotherapy in advanced Hodgkin’s disease: short-term results of 2 randomized clinical trials. Cancer Res 26:1268–1276PubMedGoogle Scholar
  133. Kinzie J, Hanks G, Maclean C, Kramer S (1983) Patterns of care study: Hodgkin’s disease relapse rate and adequacy of portals. Cancer 52:2223–2226PubMedGoogle Scholar
  134. Klimm B, Eich HT, Haverkamp H et al. (2007) Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 18 (2):357–363PubMedGoogle Scholar
  135. Kobe C, Dietlein M, Franklin J, et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112 (10):3989–3994PubMedGoogle Scholar
  136. Kriz J, Bangard C, Haverkamp U, Bongartz R et al. (2012) Quality control of involved-field radiotherapy for patients with early stage Hodgkin’s lymphoma based on a central prospective review. Comparison of the results between two study generations of the German Hodgkin Study Group. Strahlenther Onkol. Aug;188(8):660–665Google Scholar
  137. Lagarde P, Eghballi H, Bonichon F, Mascarel ID, Chauvergne J, Haerni B (1988) Brief chemotherapy associated with extended field radiotherapy in Hodgkin’s disease. Long-term results in a series of 102 patients with clinical stages I-IIIA. Eur J Cancer Clin Oncol 24:1191–1198PubMedGoogle Scholar
  138. Lee CKK, Aeppli DM, Bloomfield CD, Levitt SH (1987) Hodgkin’s disease: a reassessment of prognostic factors following modification of radiotherapy. Int J Radiat Oncol Biol Phys 13:983–991PubMedGoogle Scholar
  139. Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelson T, Rosenberg SA (1989) Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin’s disease. J Clin Oncol 7:81–91PubMedGoogle Scholar
  140. Levitt SH, Lee CKK (1983) Radical radiation therapy in the treatment of laparotomy staged Hodgkin’s disease patients. In: Amendola BE, Amendola MA (eds) Recent trends in radiation oncology and related fields. Elsevier, Amsterdam, pp 21–38Google Scholar
  141. Linch D, Winfield D, Goldstone A et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet 341:1051PubMedGoogle Scholar
  142. Lipshultz SE, Colan SD, Gelber RD, Perez AA, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood (see comments). N Engl J Med 324:808–815PubMedGoogle Scholar
  143. Lister T, Crowther D, Sutcliffe S (1989) Report of a Committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7:1630PubMedGoogle Scholar
  144. Loeffler M, Bosteanu O, Hasenclever D et al. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s disease Overview Study Group. J Clin Oncol 16:818–829PubMedGoogle Scholar
  145. Loeffler M, Diehl V, Pfreundschuh M et al. (1997) Dose-response relationship of complimentary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin’s disease. J Clin Oncol 15:2275–2287PubMedGoogle Scholar
  146. Longo D, Glatstein E, Duffey P et al. (1991) Radiation therapy versus combination chemotherapy in the treatment of earlystage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol 9:960–971Google Scholar
  147. Longo DL (1990) The use of chemotherapy in the treatment of Hodgkin’s disease. Semin Oncol 17:716–735PubMedGoogle Scholar
  148. Longo DL, Young RC, DeVita VT (1982) Chemotherapy for Hodgkin’s disease. Cancer Treatm Rep 66:925–936Google Scholar
  149. Lukes RJ, Buttler JJ (1966) The pathology and nomenclature of Hodgkin’s disease. Cancer Res 26:1063–1081PubMedGoogle Scholar
  150. Lukes RJ, Buttler JJ, Hicks EB (1966) Natural history of Hodgkin’s disease as related to its pathologic picture. Cancer 19:317–344Google Scholar
  151. Macdonald DA, Ding K, Gospodarowicz MK et al. (2007) Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 18:1680–1684PubMedGoogle Scholar
  152. MacLennan KA, Bennett MH, Tu A, Vaughan-Hudson B, Easterling MJ, Vaughan-Hudson G, Jelliffe AM (1989) Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. Cancer 64:1686–1693PubMedGoogle Scholar
  153. Mattaei D, Kliem G, Döler W et al. (1993) Vergleichende Betrachtung von Paraaortalfeldern im Rahmen der Deutschen Hodgkin-Studie. Strahlentherapie Onkol 169:590–594Google Scholar
  154. Mauch P (1998) What is the role for adjuvant radiation therapy in advanced Hodgkin’s disease. J Clin Oncol 16:815–817PubMedGoogle Scholar
  155. Mauch P, Goodman R, Hellman S (1978) The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 42:1039–1045PubMedGoogle Scholar
  156. Mauch P, Larson D, Osteen R et al. (1990) Prognostic factors for positive surgical staging in patients with Hodgkin’s disease. J Clin Oncol 8:257PubMedGoogle Scholar
  157. Mauch P, Tarbell N, Skarin A, Rosenthal D, Weinstein H (1987) Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 5:544–549PubMedGoogle Scholar
  158. Mauch P, Tarbell N, Weinstein H et al. (1988) Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576–1583PubMedGoogle Scholar
  159. Mauch PM, Kalish LA, Marcus KC et al. (1996) Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin’s diasease: long-term analysis of risk factors and outcome. Blood 87:3625–3632PubMedGoogle Scholar
  160. Mauch PM, Kalish LA, Markus KC et al. (1995) Long term survival in Hodgkin’s disease: Relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1:33–42PubMedGoogle Scholar
  161. Mefferd JM, Donaldson SS, Link MP (1989) Pediatric Hodgkin’s disease: Pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys 16:679–685PubMedGoogle Scholar
  162. Mendenhall NP, Cantor AB, Barre DM, Lynch JWL Jr, Million RR (1994) The role of prognostic factors in treatment selection for early-stage Hodgkin’s disease. Am J Clin Oncol 17:189–195PubMedGoogle Scholar
  163. Meyer RM, Gospadorowicz MK, Connors JM et al. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634–4642PubMedGoogle Scholar
  164. Miettinen M, Franssila KO, Saxen E (1983) Hodgkin’s disease, lymphocyte predominance nodular. Increased risk of subsequent non-Hodgkin’s lymphoma. Cancer 51:2293PubMedGoogle Scholar
  165. Munker R, Hasenclever D, Bosteanu O, Hiller E, Diehl V (1995) Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. J Clin Oncol 13:403PubMedGoogle Scholar
  166. Musshoff K, Boutis L (1967) Die Frage der Heilbarkeit der Lymphogranulomatose, beurteilt nach den Behandlungsergebnissen der Freiburger Medizinischen Klinik. Verh Dt Ges Inn Med 73:322–329Google Scholar
  167. Musshoff K, Boutis L (1968) Therapy results in Hodgkin’s disease. Cancer 21:1100–1113PubMedGoogle Scholar
  168. Musshoff K, Weidkuhn V, Bammert J, Felker HU (1985 a) Diagnostik und Therapie der Hodgkin’schen Erkrankung in Freiburg im Breisgau 1964–1976. 1. Mitteilung: Ergebnisse des Gesamtkollektivs. Strahlentherapie 161:581–595PubMedGoogle Scholar
  169. Musshoff K, Weidkuhn V, Bammert J, Felker HU (1985 b) Diagnostik und Therapie der Hodgkin’schen Erkrankung in Freiburg im Breisgau 1964–1976. 2. Mitteilung: Ergebnisse der Behandlungsperiode 1971–1976 im Vergleich zur Periode 1964–1971. Strahlentherapie 161:596–614PubMedGoogle Scholar
  170. Naida JD, Eisbruch A, Schoeppel SL, Sandler HM, Turrisi AT, Lichter AS (1996) Analysis of localization errors in the definition of the mantle field using a beams eye view treatment planning system. Int J Radiat Oncol Biol Phys 35:377–382PubMedGoogle Scholar
  171. Nissen N, Nordentoft A (1982) Radiotherapy versus combined modality treatment of stage I and II Hodgkin’s disease. Cancer Treat Rep 66:799–803PubMedGoogle Scholar
  172. Nogová L, Reineke T, Josting A, et al. (2005) Lymphocyte-predominant and classical Hodgkin’s lymphoma–comparison of outcomes. Eur J Haematol 66 Suppl:106–110Google Scholar
  173. Nogová L, Reineke T, Eich HT, et al. (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16 :1683–1687PubMedGoogle Scholar
  174. Noordijk E, Carde P, Hagenbeek A (1997) A combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease. Six-year results of the EORTC-GPMC controlled clinical trials “H7-VF” and “H7-U”. Int J Radiat Oncol Biol Phys 39:173 (abst)Google Scholar
  175. Noordijk E, Kluin-Nelemanns J (1997) Stage I or II Hodgkin’s disease: more chemotherapy and less irradiation. Ned Trijdschr Geneeskd 142:1281Google Scholar
  176. Noordijk EM, Carde P, Mandard AM et al. (1994) Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin’s disease. EORTC Lymphoma Cooperative Group and Pierre-et Marie-Curie. Ann Oncol 5 (Suppl 2):107–112PubMedGoogle Scholar
  177. Nordentoft A (1972) Radiotherapy in 50 cases of Hodgkin’s disease in stages I and II. Report from the Lymphogranulomatosis Committee. Ugeskr Laeger 134:2383–2385Google Scholar
  178. Pavlovsky S, Maschio M, Santarelli MT et al. (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I/II Hodgkin’s disease. J Natl Cancer Inst 80:1466PubMedGoogle Scholar
  179. Pavlovsky S, Schvartzman E, Lastiri F et al. (1997) Randomized trial of CVPP for three versus six cycles in favorable-prognosis untreated Hodgkin’s disease. J Clin Oncol 15:2652–2658PubMedGoogle Scholar
  180. Peters MV (1966) Prophylactic treatment of adjacent areas in Hodgkin’s disease. Cancer Res 26:1232–1243PubMedGoogle Scholar
  181. Peters MV (1950) A study in survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol 63:299–311Google Scholar
  182. Peters MV, Middlemiss K (1958) A study of Hodgkin’s disease treated by irradiation. Am J Roentgenol 79:114–121Google Scholar
  183. Podoloff DA (1996) Diffuse lung uptake of Ga-67 in treated lymphoma: Another milestone on the road to understanding. Radiology 199:318–320Google Scholar
  184. Press OW, Leblanc M, Lichter AS et al. (2001) Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 22:4238–4244Google Scholar
  185. Prosnitz LR, Curtis AM, Knowlton AH, Peters LM, Farber LR (1980) Supradiaphragmatic Hodgkin’s disease: significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6:809–813PubMedGoogle Scholar
  186. Prosnitz LR, Wu JJ, Yahalom J (1996) The case for adjuvant radiation therapy in advanced Hodgkin’s disease. Cancer Invest 14:361–370PubMedGoogle Scholar
  187. Pusey W (1902) Cases of sarcoma and of Hodgkin’s disease treated by exposures to x-ray: a preliminary report. JAMA 38:166–169Google Scholar
  188. Radford JA, Crowther D, Rohariner AZS et al. (1995) Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin’s disease. J Clin Oncol 13:2379PubMedGoogle Scholar
  189. Raemaekers J, Burgers M, Henry-Amar M et al. (1997) Patients with stage III/IV Hodgkin’s disease in partial remission after MOPP/ABVD chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et Marie-Curie. Ann Oncol 8 (Suppl 1):111–114PubMedGoogle Scholar
  190. Raemaekers J. (2010) EORTC/GELA/IIL randomized intergroup trial in early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with stages I/II Hodgkin’s lymphoma. Presented at the 8th International Symposium on Hodgkin Lymphoma, Cologne, Germany, October 24–26Google Scholar
  191. Reed D (1902) On the pathological changes in Hodgkin’s disease, with special reference to its relation to tuberculosis. Johns Hopkins Hosp rep 10:133Google Scholar
  192. Regula DP, Hoppe RT, Weiss LM (1988) Nodular and diffuse types of lymphocyte predominance Hodgkin’s disease. N Engl J Med 318:214Google Scholar
  193. Roach M, Brophy N, Cox R, Varghese A, Hoppe RT (1990) Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease. J Clin Oncol 8:623PubMedGoogle Scholar
  194. Ron E, Lubin JH, Shore RE et al. (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259PubMedGoogle Scholar
  195. Röntgen WG (1895) Über eine neue Art von Strahlen. Sitzungsberichte der physikalisch-medizinischen Gesellschaft zu Würzburg 30:132–141Google Scholar
  196. Rosenberg SA (1996) The management of Hodgkin’s disease: Half a century of change. Ann Oncol 7:555–560PubMedGoogle Scholar
  197. Rosenberg SA, Kaplan HS (1985) The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11:5PubMedGoogle Scholar
  198. Rosenberg SA, Kaplan HS (1970) Hodgkin’s disease and other malignant lymphomas. Calif Med 113:23–38PubMedGoogle Scholar
  199. Rosenthal SR (1936) Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis. Arch Pathol 21:628Google Scholar
  200. Rostock R, Giangreco A, Wharam M, Lenhard R, Siegelman SS, Order SE (1982) CT scan modification in the treatment of mediastinal Hodgkin’s disease. Cancer 49:2267–2275PubMedGoogle Scholar
  201. Rubin P, Casarett G (1968) Clinical radiation pathology. WB Saunders, PhiladelphiaGoogle Scholar
  202. Rueffer U, Josting A, Franklin J et al. (2004) Non-Hodgkin’s lymphoma after primary Hodgkin’s disease in the German Hodgkin’s Lymphoma Study Group: incidence, treatment, and prognosis. Ann Oncol 15 (7): 1079–1085Google Scholar
  203. Sadural E (1995) Haematological malignancies during pregnancy. Clin Obstet Gynecol 38:535PubMedGoogle Scholar
  204. Salloum E, Doria R, Schubert W et al. (1996) Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14:2435–2443PubMedGoogle Scholar
  205. Santoro A (1997) Annual Conference of ECCO. Hamburg (abstr.)Google Scholar
  206. Santoro A, Bonadonna G, Valagussa P et al. (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27–37PubMedGoogle Scholar
  207. Santoro A, Bonfante V, Viviani S et al. (1996) Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin’s disease (HD). Proc Am Soc Clin Oncol 15:415Google Scholar
  208. Santoro A, Viviani S, Villarreal C et al. (1986) Salvage therapy in Hodgkin’s disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70:343PubMedGoogle Scholar
  209. Santoro A, Viviani S, Zucali R et al. (1983) Comparative results and toxicity of MOPP vs ABVD combined with radiotherapy (RT) in PS IIB, III (A, B) Hodgkin’s disease (HD). Annual Meeting American Society of Clinical Oncology, San Diego, CAGoogle Scholar
  210. Schewe K, Reavis J, Kun L, Cox J (1988) Total dose, fraction size, and tumor volume in the local control of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 15:25–28PubMedGoogle Scholar
  211. Schmitz N, Sextro M, Pfistner B (1999) HDR-1: high-dose therapy (HDT) followed by hematopoetic stem cell tranplantation (HSCT) for relapsed chemosensitive Hodgkin’s disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 18 (Suppl 5):18Google Scholar
  212. Schmoll H (1982) Review of etoposide single-agent activity. Cancer Treatment Rev 9 (Suppl):21–30Google Scholar
  213. Schomberg PJ, Evans RG, O’Connel MJ et al. (1984) Prognostic significance of mediastinal mass in adult Hodgkin’s disease. Cancer 53:324–328PubMedGoogle Scholar
  214. Schulz H, Rehwald U, Morschhauser F et al. (2008) Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111 (1):109–111PubMedGoogle Scholar
  215. Senn N (1903) Therapeutical value of roentgen ray in treatment of pseudoleukemia. NY Med J 77:665–668Google Scholar
  216. Shahidi M, Kamangari N, Ashley S et al. (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78:1–5PubMedGoogle Scholar
  217. Shore T, Nelson N, Weinerman B (1990) A meta-analysis of stages I and II Hodgkin’s disease. Cancer 65:1155–1160PubMedGoogle Scholar
  218. Sienawski M, Franklin J, Nogova L et al. (2007) Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol. 25 (15):2000–2005Google Scholar
  219. Sommers R, Tubiana M, Henry-Amar M (1989) EORTC lymphoma cooperative group studies in clinical stage I-II Hodgkin’s disease 1963–1987. Rec Results Cancer Res 117:175–181Google Scholar
  220. Specht L (1996) Prognostic factors in Hodgkin’s disease. Semin Radiat Oncol 6:146Google Scholar
  221. Specht L, Gray R, Clarke M, Peto R (1998) The influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin’s disease: a metaanalysis of 23 randomized trials involving 3888 patients. J Clin Oncol 16:830–843PubMedGoogle Scholar
  222. Specht L, Nissen N (1989) Hodgkins disease and age. Eur J Haematol 43:127PubMedGoogle Scholar
  223. Specht LK, Hasenclever D (1999) Prognostic factors of Hodgkin’s disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 295–326Google Scholar
  224. Stein H, Schwarting R, Dallenbach F, Dienemann D (1989) Immunology of Hodgkin and Reed-Sternberg cells. Recent Results Cancer Res 117:14–27PubMedGoogle Scholar
  225. Sternberg C (1898) Über eine eigenartige unter dem Bilde der pseudoleukämie verlaufende Tuberkulose des lymphatischen Apparates. Ztschr Heilk 19:21Google Scholar
  226. Straus DJ, Myers L, Passe S (1980) The eight-drug/radiation therapy program (MOPP/ABVD/RT) for advanced Hodgkin’s disease – a follow-up report. Cancer 46:233–239PubMedGoogle Scholar
  227. Straus DJ, Yahalom J, Gaynor J et al. (1992) Four cycles of chemotherapy and regional radiation therapy for clinical earlystage and intermediate-stage Hodgkin’s disease. Cancer 69:1052–1060PubMedGoogle Scholar
  228. Sutcliffe S, Gospodarowicz M, Bergsagel D et al. (1985) Prognostic groups for management of localized Hodgkin’s disease. J Clin Oncol 3:393PubMedGoogle Scholar
  229. Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, Lennan KAM (1992) Risk of second primary cancer after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. Br J Med 304:1137–1143Google Scholar
  230. Swerdlow AJ, Douglas AJ, Hudson V et al. (1993) Risk of second primary cancer after Hodgkin’s disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin’s disease and splenectomy. Br J Cancer 68:1006–1011PubMedGoogle Scholar
  231. Tarbell N, Thompson L, Mauch P (1990) Thoracic irradiation in Hodgkin’s disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 18:275PubMedGoogle Scholar
  232. Tesch H, Diehl V, Lathan B et al. (1998) Moderate dose escalation for advanced stage Hodgkin’s disease using bleomycin, etoposid, adriamycin, cyclophosphamide, vincristine, procarbacine and prednison scheme and adjuvant radiotherapy: A study of the German Hodgkin Lymphoma Study Group. Blood 92:4560PubMedGoogle Scholar
  233. Thompson DE, Mabuchi K, Ron E et al. (1994) Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958–1987. Radiat Res 137:17. Published erratum appears in Radiat Res 139:129Google Scholar
  234. Torti FM, Portlock CS, Rosenberg SA, Kaplan HS (1981) Extralymphatic Hodgkin’s disease. Prognosis and response to therapy. Am J Med 70:487–492PubMedGoogle Scholar
  235. Tubiana M, Henry-Amar M, Carde P (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73:47PubMedGoogle Scholar
  236. Tubiana M, Henry-Amar M, Hayat M et al. (1984) Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 54:885–894PubMedGoogle Scholar
  237. Tubiana M, Mathe G, Laugier A (1968) Current clinical trials in the radiotherapy of Hodgkin’s disease. Cancer Res 26:1277–1278Google Scholar
  238. Tucker M (1993) Second cancers following Hodgkin’s disease. Hematol Clin North Am 7:389Google Scholar
  239. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 318:76PubMedGoogle Scholar
  240. Tucker MA, Jones PH, Boice JD et al. (1991) Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 51:2885PubMedGoogle Scholar
  241. Uematsu M, Tarbell NJ, Siver B et al. (1993) Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin’s disease in relapse after initial combination chemotherapy. Cancer 72:207PubMedGoogle Scholar
  242. Valagussa P (1993) Second neoplasms following treatment of Hodgkin’s disease. Curr Opin Oncol 5:805PubMedGoogle Scholar
  243. Van Leeuwen F, Sommers R, Taal B (1989) Increased risk of lung cancer, non-Hodgkin’s lymphoma and leukemia following Hodgkin’s disease. J Clin Oncol 7:1046PubMedGoogle Scholar
  244. Van Leeuwen FE, Klokman WJ, Hagenbeck A et al. (1994) Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 13:312–325Google Scholar
  245. Van Leeuwen FE, Swerdlow AJ, Valagussa P (1999) Second Cancers after treatment of Hodgkin’s disease. In: Mauch PM, Armittage JO, Diehl V, Hoppe RT, Weiss LM (eds) Hodgkin’s disease. Lippincott Williams & Wilkins, Philadelphia, pp 607–633Google Scholar
  246. Vaughan-Hudson B, Maclennan KA, Bennett MH, Easterling MJ, Hudson GV, Jelliffe AM (1987) Systemic disturbance in Hodgkin’s disease and its relation to histopathology and prognosis (BNLI report no. 30). Clin Radiol 38:257–261PubMedGoogle Scholar
  247. Vijayakumar S (1992) What dose in Hodgkin’s disease? A review of dose-response data. Onkologie 15:190–196Google Scholar
  248. Vijayakumar S, Myrianthopoulos L (1992) An updated dose-response analysis in Hodgkin’s disease. Radiother Oncol 24:1–13PubMedGoogle Scholar
  249. Vijayakumar S, Rosenberg I, Brandt T, Spelbrink D, Rubin S (1992) Quantification of doses to mediastinal lymph nodes in Hodgkin’s disease. Med Dosimetry 17:87–94Google Scholar
  250. Viviani S, Bonadonna G, Santoro A et al. (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 14:1421PubMedGoogle Scholar
  251. Westling P (1965) Studies of the prognosis in Hodgkin’s disease. Acta Radiol 245:5Google Scholar
  252. Wiernik P, Lichtenfeld D (1975) Combined modality therapy for localized Hodgkin’s disease. Oncology 32:208–213PubMedGoogle Scholar
  253. Wilks S (1865) Case of enlargement of the lymphatic glands and spleen (or Hodgkin’s disease), with remarks. Guy’s Hosp Rep 11:56–67Google Scholar
  254. Wirth A, Corry J, Laidlaw C, Matthews J, Liew KH (1997) Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 39:599–607PubMedGoogle Scholar
  255. Zietman AL, Linggood RM, Brookes AB, Convey K, Piro A (1991) Radiation therapy in the management of early stage Hodgkin’s disease. Cancer 68:1869PubMedGoogle Scholar
  256. Zittoun R, Audebert A, Hoerni B et al. (1985) Extended versus involved field irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3:207–214PubMedGoogle Scholar

Zu Non-Hodgkin-Lymphome

  1. Aviles A, Delgado S, Fernandez R et al. (2002) Combined therapy in advanced stages (III and IV) of follicular lymphoma increases the possibility of cure: results of a large controlled clinical trial. Eur J Haematol 68:144–149PubMedGoogle Scholar
  2. Aviles A, Delgado S, Nambo MJ et al. (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients with stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30:799–803PubMedGoogle Scholar
  3. Bay JY, Gomez F, Sebban C et al. (1998) The International Prgnostic Index correlates to survival in patients withaggressive lymphoma in relapse. Analysis of the PARMA trial. Blood 92:3562–3568Google Scholar
  4. Besa PC, McLaughlin PW, Cox JD et al. (1995) Long term assesment of patterns of treatment failure and survival in patients with stage I and II follicular lymphoma. Cancer 75:2361–2367PubMedGoogle Scholar
  5. Bhatia S, Arnold C, Paulino AC et al. (2002) Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 54:818–823PubMedGoogle Scholar
  6. Bischof M, Zierhut D, Gutwein S et al. (2001) Die Venenverschlusskranheit nach infradiaphragmaler total lymphatischer Bestrahlung. Strahlenther Onkol 177:296–301PubMedGoogle Scholar
  7. Bischof M, Karagiozidis M, Krempien R et al. (2007) Radiotherapy for orbital lymphoma: outcome and late effects. Strahlentherapie Onkologie 183:17–22Google Scholar
  8. Bolek TW, Moyses HM, Marcus RB Jr et al. (1999) Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 44:31–36PubMedGoogle Scholar
  9. Bunn PA, Hoffmann SJ, Norris D et al. (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary Syndrome). Ann Internal Med 121:592–602Google Scholar
  10. Coiffier B, Lepage E, Briere J (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients. N Engl J Med 346:235–242PubMedGoogle Scholar
  11. DeAngelis LM (1995) Current management of the primary central nervous system lymphoma. Oncology 9:63–71PubMedGoogle Scholar
  12. De Angelis LM, Seiferheld W, Schold SC (2002) Radiation therapy oncology group study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: RTOG-study 93-10. J Clin Onc 20:4643–4648Google Scholar
  13. Esik O, Ikeda H, Mukai K et al. (1996) A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin’s lymphomas. Radiother Oncol. 38:13–18PubMedGoogle Scholar
  14. Fitzpatrick PJ, Macko S. (1984) Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 10:333–340PubMedGoogle Scholar
  15. Funk A, Hensley F, Krempien R et al. (2008) Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma. Eur J Dermatol 18:308–312PubMedGoogle Scholar
  16. Galieni P, Polito E, Leccisotti A et al. (1997) Localized orbital lymphoma. Haematologica 82:436–439PubMedGoogle Scholar
  17. Goffinet DR, Glatstein E, Fuks Z (1976) Abdominal irradiation in non-Hodgkin´s lymphoma. Cancer 37:2797PubMedGoogle Scholar
  18. Haas RL, Poortmans P, de Jong D et al. (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphoma. J Clin Onc 21:2474–2480Google Scholar
  19. Harris NL, Jaffe ES, Diebold J, Flandrin G, Müller-Hermelink HK, Vardiman J (2000) Lymphoma classification from controversy to consensus: The R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 11:3–10PubMedGoogle Scholar
  20. Held G, Schubert J, Rübe C et al. (2006) Fortschritte in der Behandlung der diffus-großzelligen Lymphome. Onkologe 12:619–627Google Scholar
  21. Hiddemann W, Unterhalt M, Wandt H (1999) Myeloablative radiochemotherapy followed by blood-stemcell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: results of a prospective randomized trial of the GLSG. Blood 94 (Suppl.):610AGoogle Scholar
  22. Jones GW, Tadros A, Hodson DJ et al. (1994) Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 to 35 Gy. Int J Radiat Oncol Biol Phys 28:839–845PubMedGoogle Scholar
  23. Koch P, Berdel WE, Willich N et al. (2001) Grading in marginal-zone lymphomas. J Clin Oncol 18:2788Google Scholar
  24. Koch P, Lehnert T, Willich N (2001) Gastrointestinale Lymphome. Onkologe 7:982–989Google Scholar
  25. Koch P, Valle F del, Berdel WE et al. (2001) Primary gastrointestinal non-Hodgkin´s lymphoma I: anatomical and histological distribution, clinical features and survival data of 371 patients registered in the German Multicenter Study (GIT NHL 01/ 92). J Clin Oncol 19:3861–3873PubMedGoogle Scholar
  26. Korfel A, Weller M, Plasswilm L, Bamberg M, Thiel E (2001) Primäre ZNS-Lymphome des immunkompetenten Patienten. Onkologe 7:990–997Google Scholar
  27. Lawrence T, Urba W, Steinberg S et al. (1988) Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 14:417–424PubMedGoogle Scholar
  28. Le QT, Eulau SM, George TI et al. (2002) Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 52:657–663PubMedGoogle Scholar
  29. Levitt S, Bloomfield C, Fizzera G et al. (1980) Curative radiotherapy for localized diffuse histiocytic lymphoma. Cancer Treat Rep 64:175–177PubMedGoogle Scholar
  30. MacManus MP, Bowie CA, Hoppe RT (1998) What is the prognosis for patients who relapse after primary radiation therapy for early-stage low-grade follicular lymphoma? Int J Radiat Oncol Biol Phys 42:365–371Google Scholar
  31. Martinet S, Ozsahin M, Belkacemi Y et al. (2003) Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 55:892–898PubMedGoogle Scholar
  32. Micaily B, Moser C, Vonderheid EC et al. (1990) The radiation therapy of early stage cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 18:1333–1339PubMedGoogle Scholar
  33. Moser EC, Kluin-Nelemans HC, Carde P et al. (2006) Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin’s lymphoma. In J Radiat Oncol Biol Phys 66:1168–1177Google Scholar
  34. NHL, Lymphoma, pathologic, Classification, Project (1982) National cancer institute sponsored study of classification of Non-Hodgkin´s Lymphomas. Cancer 49:2112–2135Google Scholar
  35. O´Brien P, Roos D, Pratt G et al. (2000) Phase II multicenter study of brief single agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526Google Scholar
  36. Parsonett J, Hansen S, Rodriguez L (1994) Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330:1267–1271Google Scholar
  37. Pelloski CE, Wilder RB, Ha CS et al. (2001) Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiother Oncol 59:145–151PubMedGoogle Scholar
  38. Pfreundschuh M, Trümper L, Osterborg A et al. (2006) CHOP-like chemotherapy plus Rituximab versus CHOP-like chemotherapy alone in young patients with good- prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391PubMedGoogle Scholar
  39. Poortmanns PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. (2003) High-dose methotrexate-based chemotherapy followed by consolidation radiotherapy in non-AIDS-related primary central nervous system lymphoma: EORTC phase-II trail 20962. J Clin Onc 21:4483–4488Google Scholar
  40. Rappaport H (1966) Tumors of the hematopoietic system. In: Atlas of tumor pathology. Sect. II. Armed Forces Institute of Pathology, Washington,DC.Google Scholar
  41. Rockwood EJ, Zakov ZN, Bay JW (1984) Combined malignant lymphoma of the eye and CNS. J Neurosurg 61:369–373PubMedGoogle Scholar
  42. Rübe C, Nguyen P, Klöss M et al. (2001) Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Haematol 80 (Suppl.):84–85Google Scholar
  43. Sack H, Hoederath M, Stuschke W et al. (1998) Strahlenbehandlung von follikulären Keimzentrumslymphomen. Strahlenther Onkol;174:178–185PubMedGoogle Scholar
  44. Schelgel U, Korfel A, Thiel E et al. (2009) Primäre ZNS-Lymphome. Onkologe 15:211–221Google Scholar
  45. Schmidberger H, Hess CF, Rübe C (2001) Stellenwert der Strahlentherapie bei nodalen Non-Hodgkin Lymphomen in lokalen und fortgeschrittenen Stadien. Onkologe 7:960–968Google Scholar
  46. Stansfield AG, Diebold J, Noel H (1988) Kiel Classification. Lancet 1:292–293Google Scholar
  47. Stuschke M, Hoederath A, Sack H et al. (1997) Extended field and total central lymphatic radiotherapy for early stages nodal centroblastic-centrocytic lymphoma: results of a prospective multicenter study. Cancer 80:2273–2284PubMedGoogle Scholar
  48. Sweet D, Kinzie J, Gaeke M et al. (1981) Survival of patients with localized diffuse histiocytic lymphoma. Blood 58:1218–1223PubMedGoogle Scholar
  49. Shipp MA, Harrington DP et al. (1993) The International Non-Hodgkin´s Lymphoma prognostic factors project. A predictive model for aggressive Non-Hodgkin´s lympoma. N Engl J Med 329:987–949Google Scholar
  50. Welch K, Finkbeiner W, Alpers CE et al. (1984) Autopsy findings in the aquired immune deficiency syndrome. JAMA 1984 252:1152–1159PubMedGoogle Scholar
  51. Wilder RB, Tucker SL, Chul S et al. (2001) Radiation therapy after partial response to CHOP chemotherapy for aggressive lymphomas. Int J Radiat Oncol Biol Phys 50:743–749PubMedGoogle Scholar
  52. Wilder RB, Tucker SL, Chul S, Rodriguez MA et al. (2001) Dose response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. Int J Radiat Oncol Biol Phys 49:17–22PubMedGoogle Scholar
  53. Woodman R, Shin K, Pineo G et al. (1985) Primary non-Hodgkin´s lymphoma of the brain: a review. Medicine 64:425–430PubMedGoogle Scholar
  54. Ysebaert L, Truc G, Dalac S et al. (2004) Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58:1128–1134PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • H.T. Eich
    • 2
  • J. Kriz
    • 3
  • M. Bischof
    • 1
  1. 1.Abteilung für Radioonkologie und StrahlentherapieRadiologische KlinikHeidelbergDeutschland
  2. 2.Klinik für Strahlentherapie & RadioonkologieUniversitätsklinikum MünsterMünsterDeutschland
  3. 3.Klinik und Poliklinik für StrahlentherapieUniversitätsklinikum MünsterMünsterDeutschland

Personalised recommendations